Dr David Kaslow, Vice President of Infectious Diseases and Vaccines at Merck to give Keynote presentation at 3rd Modern Drug Discovery and Development Summit

Released on: October 17, 2007, 9:17 am

Press Release Author: GTCbio

Industry: Biotech

Press Release Summary: Dr. David Kaslow, VP of Infectious Diseases and Vaccines at
Merck will give the Keynote presentation at GTCbio's Biological Therapeutics
conference - one of six tracks at the 3rd Modern Drug Discovery & Development Summit
on November 28-30, 2007 at the Hyatt Regency San Francisco Airport.



Press Release Body: MONROVIA, CA - Dr. David Kaslow, Vice President of Infectious
Diseases and Vaccines at Merck & Company will give the Keynote presentation at
GTCbio's Biological Therapeutics conference - one of six tracks at the 3rd Modern
Drug Discovery & Development Summit on November 28-30, 2007 at the Hyatt Regency San
Francisco Airport.

Dr. Kaslow's presentation will cover the progress toward a multi-dimensional
approach to infectious diseases product development by integrating diagnostics,
drugs, and biologics. Historically, anti-infectives and biologics (antibodies and
vaccines), in addition to general public health measures, have had an immense impact
on alleviating the healthcare burden due to infectious diseases. With perhaps a few
exceptions (e.g., Variola), however, each new specific therapeutic advance has been
ultimately met by some counter-response from the microbial world. Given those
conditions, it should come as no surprise that although a single dimensional
therapeutic approach may provide a near-term gain, such an approach wills an
unlikely result in a durable effective intervention. A multi-dimensional approach,
which may include diagnostics, drugs and biologics, to prevent and/or treat
infections by these evolving microbial pathogens may be necessary to add new
products with real, long-lasting value to our armamentarium. Building an integrated
approach by appropriately incorporating new diagnostics and integrating multiple
interventional modalities may provide a more valuable and sustainable next
generation of products. Examples of such approaches will be presented.

The 3rd Modern Drug Discovery & Development Summit features over 150 speakers
participating in 6 concurrent conferences, 6 study sessions and 3 pre-conference
workshops. Tracks include Biological Therapeutics, Drug Delivery Technology,
Translational Medicine, Drug Design and Lead Optimization, Emerging Targets, and
Pharmaco - Kinetics, Dynamics, Genomics and Genetics. For more information, visit
www.gtcbio.com.


ABOUT GTCbio

GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government
organizations, and the financial community.

GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company
founded in 2002.

Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, raniah@gtcbio.com


Web Site: http://www.gtcbio.com

Contact Details: GTCbio
434 W Foothill Blvd.
Monrovia, CA 91016
626) 256-6405

  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •